Related Experiment Video
Updated: Aug 9, 2025
04:53
An In Vitro Approach to Photodynamic Therapy
Published on: August 17, 2018
8.8K
Genetic deviation associated with photodynamic therapy in HeLa cell
Asiye Gok Yurttas1, Zehra Okat2, Tugba Elgun3
1Department of Biochemistry, Faculty of Pharmacy, Istanbul Health and Technology University, Istanbul, Turkey.
Photodiagnosis and Photodynamic Therapy
|February 22, 2023
Summary
Photodynamic therapy using phthalocyanine L1ZnPC shows promise for cancer treatment. This new photosensitizer induced significant cancer cell death and apoptosis in HELA cells, warranting further investigation.
Area of Science:
- Photodynamic therapy
- Cancer research
- Molecular biology
Background:
- Photodynamic therapy (PDT) is a cancer treatment utilizing photosensitizers to generate singlet oxygen.
- Phthalocyanines are effective photosensitizers, absorbing light in the 600-700 nm range for PDT applications.
Purpose of the Study:
- To investigate the anti-cancer activity of phthalocyanine L1ZnPC in HELA cells.
- To analyze cancer cell death pathways and gene expression changes induced by L1ZnPC-mediated PDT.
Main Methods:
- Cytotoxicity and apoptosis induction by L1ZnPC were assessed using flow cytometry.
- Gene expression analysis was performed using quantitative PCR (q-PCR) with the 2-∆∆Ct method.
- Statistical analysis included One-Way ANOVA and Tukey-Kramer tests.
Main Results:
- L1ZnPC combined with PDT resulted in an 80% apoptosis rate in HELA cancer cells.
- q-PCR identified eight significant cancer-associated genes affected by the treatment.
- L1ZnPC demonstrated significant cytotoxic effects on the HELA cell line.
Conclusions:
- L1ZnPC is a promising new phthalocyanine for photodynamic therapy.
- Further studies are required to validate these findings in different cancer cell lines and elucidate the underlying mechanisms.
- Detailed analysis of signaling pathways and mechanism of action is necessary.
